Sotatercept-csrk (Winrevair; Merck &Co. Inc.) is an activin signaling inhibitor indicated for the treatment of adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
